FDC Limited launches Favenza – oral suspension of Covid drug Favipiravir
FDC Limited has launched Favenza Oral Suspension – an oral suspension of Favipiravir, in India for the treatment of mild to moderate cases of Covid-19.
According to the Indian pharma company, the Covid-19 drug can be purchased on showing prescriptions at all hospital pharmacies and retail medical outlets in India.
According to FDC Limited, Favenza suspension is unique because of its convenient loading dose (Day 1) of 18 ml in the morning followed by 18 ml in the evening. This is equivalent to taking nine tablets of Favipiravir 400mg, thereby making the process of treating Covid-19 hassle-free.
Mayank Tikkha – General Manager – Business Development and Commercial Excellence, FDC Ltd, said: “With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease. In order to combat Covid-19, we believe in offering best efficacy along with convenience to our patients and as such we have focused our efforts in making the process of Covid-19 treatment hassle-free.”